Alternative strategies for the management of respiratory failure in the newborn--clinical realities.
Following the introduction of surfactant in the early 1990s and the growing use of antenatal steroids since that time, the number of infants, term and preterm, suffering severe acute respiratory failure has declined. However, such babies do still occur and their management causes much debate and concern not least because of the recognised high risk of adverse outcome in these babies. This article reviews the therapeutic options available when other more routine strategies fail.
Field
David
D
Department of Child Health, Robert Kilpatrick Clinical Sciences Building, University of Leicester, Leicester LE2 7LX, UK. david.field@uhl-tr.nhs.uk
D000208:Acute Disease; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002983:Clinical Competence; D003131:Combined Modality Therapy; D015199:Extracorporeal Membrane Oxygenation / Q000379:methods*; D006612:High-Frequency Ventilation / Q000379:methods*; D006801:Humans; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal; D021061:Liquid Ventilation / Q000379:methods*; D009569:Nitric Oxide / Q000627:therapeutic use*; D011785:Quality Assurance, Health Care; D016032:Randomized Controlled Trials as Topic; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy*; D014481:United States
D001993:Bronchodilator Agents; D009569:Nitric Oxide